People: Vision Sciences Inc (VSCI.O)
VSCI.O on Consolidated Issue listed on NASDAQ Capital Market
1.02USD
23 May 2013
1.02USD
23 May 2013
Price Change (% chg)
$-0.07 (-6.42%)
$-0.07 (-6.42%)
Prev Close
$1.09
$1.09
Open
$1.07
$1.07
Day's High
$1.10
$1.10
Day's Low
$1.02
$1.02
Volume
6,300
6,300
Avg. Vol
30,783
30,783
52-wk High
$1.70
$1.70
52-wk Low
$0.91
$0.91
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Lewis Pell |
69 | 2005 | Chairman of the Board |
Howard Zauberman |
60 | 2013 | Interim Chief Executive Officer |
Keith Darragh |
2012 | Principal Financial Officer, Principal Accounting Officer, Vice President - Finance | |
Mark Landman |
57 | 2007 | Vice President - Disposables Operations |
Jitendra Patel |
58 | 2000 | Vice President - Industrial Division |
Warren Bielke |
65 | 2011 | Director - Strategic Initiatives, Director |
Cynthia Ansari |
2013 | Director | |
David Anderson |
59 | 2005 | Independent Director |
Lothar Koob |
63 | 2009 | Independent Director |
Katsumi Oneda |
74 | 2005 | Independent Director |
Cheryl Pegus |
48 | 2013 | Independent Director |
Bruce Polsky |
58 | 2010 | Independent Director |
John Rydzewski |
59 | 2009 | Independent Director |
Biographies
| Name | Description |
|---|---|
Lewis Pell |
Mr. Lewis C. Pell serves as Chairman of the Board of Vision Sciences Inc., since October 2005. Prior to that, Mr. Pell served as Vice-Chairman of Board of Directors since 1992. Mr. Pell is a founder or co-founder and chairman and director of several privately held medical device companies and is the chairman of Photomedex, Inc., a publicly-traded dermatology company. |
Howard Zauberman |
Mr. Howard I. Zauberman is Interim Chief Executive Officer of Vision Sciences, Inc. He has over 30 years of experience in the medical products industry. Prior to joining the Company, Mr. Zauberman was Vice President of Business Development at Henry Schein, Inc., a global healthcare distributor serving office based medical practitioners, from 2005 through 2012. Mr. Zauberman also served as a Special Venture Partner at Galen Partners, a healthcare growth equity and late stage venture capital firm, focused on technology enabled services, medical devices and specialty pharmaceuticals. Prior to this, Mr. Zauberman held senior management positions at ETHICON, Inc. a Johnson & Johnson company and Pfizer, Inc. Mr. Zauberman has a Masters of Engineering Management from Northwestern University, a Bachelor of Science from Columbia University in mechanical engineering and a Bachelors degree from Queens College. |
Keith Darragh |
Mr. Keith Darragh is no longer Principal Financial Officer, Principal Accounting Officer, Vice President - Finance of Vision-Sciences, Inc., effective May 17, 2013. Mr. Darragh joined the Company in August 2009 as Corporate Controller and became the Vice President of Finance in September 2011. Prior to joining Vision-Sciences, from 2006 to 2009, he was Director of Corporate Accounting & Financial Reporting at Datascope Corp., a publicly traded medical device manufacturer that was acquired by Getinge Group. Mr. Darragh held positions of increasing responsibility in accounting and finance at SYMS Corp, Sankyo Pharma, Inc., and Genzyme Biosurgery Corp. Mr. Darragh is a certified public accountant and chartered global management accountant, and holds a B.S. (summa cum laude) and an M.B.A. from Montclair State University. |
Mark Landman |
Mr. Mark S. Landman serves as Vice President - Disposables Operations of Vision Sciences Inc. He served as Vice President of Medical Division since July 1999. Mr. Landman joined the company from Boston Scientific in January 1991 and served in a variety of roles in product development, project management, manufacturing engineering, and material control from that date to July 1999. |
Jitendra Patel |
Mr. Jitendra Patel serves as Vice President - Industrial Division of Vision Sciences Inc. From August 1995 to July 2000, he served as the Manager of Sales and Marketing for that division. |
Warren Bielke |
Mr. Warren Bielke serves as Director - Strategic Initiatives, Director of Vision Sciences Inc., since 2005. Previously he served as Interim Chief Executive Officer from November 9, 2009 to August 11, 2011. From April 2009 to November 9, 2009 he provided consulting services to Vision-Sciences. Prior to April 2009, he served as a business consultant and an investor. He has served as President and Chief Executive Officer of Vertebral Technologies, Inc., a developer of spinal implants from 2005 to 2006. Prior to that, Mr. Bielke was self-employed as a consultant and investor with start-up businesses from 1999 to 2005. Mr. Bielke is a director of two other private companies. |
Cynthia Ansari |
Ms. Cynthia F. Ansari serves as Director of Vision Sciences Inc. Prior to joining the company, Ms. Ansari served from 2007 to 2011 as Vice President of Global Marketing for Stryker Spine, one of the world’s medical technology companies. From 1992 to 2007, Ms. Ansari held positions of increasing responsibility in sales and marketing at Stryker, including over a decade developing products for the endoscopic market. At Stryker, she led a global team of professionals to launch numerous products and transform the Stryker Spine Marketing Organization. Ms. Ansari began her career at Motorola, Inc. where she earned numerous achievements, including the company’s prestigious “Salesperson of the Year” award in 1991. Ms. Ansari has a B.A. in Economics from the University of Maryland. She has also participated in Executive Leadership Programs at Harvard Business School. |
David Anderson |
Mr. David W. Anderson serves as an Independent Director of Vision Sciences Inc. He Anderson has served as President, Chief Executive Officer and director of Gentis, Inc. since 2004. Prior to that, Mr. Anderson was the President, Chief Executive Officer and director of Sterilox Technologies, Inc. from 2000 to 2004. Mr. Anderson is a director of Photomedex Inc., Inion Ltd. and several private companies. Mr. Anderson serves on the company's Audit, Governance and Nominating, and Compensation Committees. |
Lothar Koob |
Mr. Lothar Koob serves as an Independent Director of Vision Sciences Inc. He has been a General Partner of Extera Partners LLC, a life science strategic partnering and product commercialization firm located in Cambridge, MA, since 2007. Between 2001 and 2006, Mr. Koob was an Executive Vice President of Analogic Corporation (Analogic) of Peabody, MA. Prior to that, he was with Zeiss/Humphrey as its President of Worldwide Ophthalmic Systems Business and prior to that he spent 24 years in various positions at Siemens Medical where he also served as the General Manager of the MRI and Ultrasound worldwide business units. Mr. Koob is currently a director of Ultrasonix Medical and Helix Medical. In the past five years he has also been a director of BK Medical and Sky Computers, which are both subsidiaries of Analogic. Mr. Koob serves on Audit, Governance and Nominating, and Compensation Committees. |
Katsumi Oneda |
Mr. Katsumi Oneda serves as an Independent Director of Vision Sciences Inc. He is a co-founder of Vision-Sciences and served as Chairman of the Board of Directors from 1990 to 1991 and again from 1993 to 2005. From 1993 through 2003, he also served as President and Chief Executive Officer. He served as Vice-Chairman of Board from 1992 to 1993 Mr. Oneda is a director of Photomedex, Inc. and of a private company. |
Cheryl Pegus |
Dr. Cheryl Pegus, M.D., MPH, is appointed as Independent Director of Vision Sciences, Inc. Dr. Pegus is a Director of Glytec, a glycemic clinical software company and Strategic Advisor to HealthFleet, Inc, an online interactive prevention company. She is the 2013 President-Elect and a member of the Board of the American Heart Association (AHA) Founder’s Affiliate. Previously, she was the Chief Medical Officer for Walgreens. She has served as the General Manager and Chief Medical Officer for SymCare Personalized Health Solutions, Inc., and the Head of Clinical Products for Aetna’s Medical Products Business Unit. Dr. Pegus also served as the Medical Director for the Cardiovascular Risk Factors Group at Pfizer Pharmaceuticals. She is a Member of the Dean’s Circle at Weill Cornell Medical College. She received an M.P.H. from Columbia University School of Public Health, an M.D. from Cornell University Medical College and completed her internal medicine residency and cardiology fellowship at New York Hospital-Cornell. |
Bruce Polsky |
Dr. Bruce Polsky serves as an Independent Director of Vision Sciences Inc. He is currently Chairman of the Department of Medicine, Chief of the Division of Infectious Diseases, Hospital Epidemiologist, and Medical Director of the Clinical Virology Laboratory at St. Luke's-Roosevelt Hospital Center in New York City. Dr. Polsky also serves as the John H. Keating Sr. Professor of Clinical Medicine at the College of Physicians and Surgeons of Columbia University. Prior to joining St. Luke's-Roosevelt in 1998, Dr. Polsky was Associate Professor of Medicine at Cornell University Medical College. Dr. Polsky is a graduate of the University of Michigan and the Wayne State University School of Medicine. His post-graduate training in Internal Medicine was at Montefiore Medical Center and the Albert Einstein College of Medicine in New York City. |
John Rydzewski |
Mr. John J. Rydzewski, CPA, serves as an Independent Director of Vision Sciences Inc., since June 2009. He is the Executive Chairman of Enumeral Biomedical Corp., a privately-held company engaged in the discovery of native human monoclonal antibodies for use in disease diagnosis and treatment. Prior to joining Enumeral in October 2011, he was a Managing Director of Christofferson, Robb & Co. where he was responsible for life science investments since 2006. Mr. Rydzewski was previously a healthcare investment banker and a manager at Price, Waterhouse & Co. He currently serves as Executive Chairman of Enumeral Biomedical Corp., Director of Fidelis Care New York, and Vice Chairman of RAND Health, the healthcare policy research unit of the RAND Corporation. He received both MBA and BS degrees from The Wharton School of the University of Pennsylvania and he obtained his C.P.A license in Missouri. Mr. Rydzewski serves on Audit, Governance and Nominating, and Compensation Committees. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Lewis Pell |
110,814 |
Howard Zauberman |
-- |
Keith Darragh |
-- |
Mark Landman |
338,082 |
Jitendra Patel |
219,870 |
Warren Bielke |
678,579 |
Cynthia Ansari |
1,650,420 |
David Anderson |
-- |
Lothar Koob |
-- |
Katsumi Oneda |
109,200 |
Cheryl Pegus |
-- |
Bruce Polsky |
-- |
John Rydzewski |
-- |
As Of 30 Mar 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Lewis Pell |
0 | 0 |
Howard Zauberman |
0 | 0 |
Keith Darragh |
0 | 0 |
Mark Landman |
258,750 | 147,475 |
Jitendra Patel |
0 | 0 |
Warren Bielke |
0 | 0 |
Cynthia Ansari |
0 | 0 |
David Anderson |
0 | 0 |
Lothar Koob |
0 | 0 |
Katsumi Oneda |
125,000 | 0 |
Cheryl Pegus |
0 | 0 |
Bruce Polsky |
0 | 0 |
John Rydzewski |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
PELL LEWIS C |
15,000 | $1.15 |
PELL LEWIS C |
15,000 | $1.13 |
PELL LEWIS C |
10,000 | $1.11 |
PELL LEWIS C |
10,000 | $1.13 |
PELL LEWIS C |
25,000 | $1.09 |
PELL LEWIS C |
10,000 | $1.12 |
PELL LEWIS C |
25,000 | $1.07 |
PELL LEWIS C |
25,000 | $1.09 |
PELL LEWIS C |
10,000 | $1.03 |
PELL LEWIS C |
5,000 | $1.09 |
PELL LEWIS C |
5,000 | $1.08 |
PELL LEWIS C |
5,000 | $1.06 |
PELL LEWIS C |
61,266 | $1.00 |
PELL LEWIS C |
25,000 | $0.99 |
PELL LEWIS C |
5,000 | $0.99 |
PELL LEWIS C |
9,000 | $0.99 |
PELL LEWIS C |
22,900 | $1.00 |
PELL LEWIS C |
25,000 | $1.01 |
PELL LEWIS C |
10,000 | $1.09 |
PELL LEWIS C |
10,000 | $1.13 |
PELL LEWIS C |
7,500 | $1.09 |
PELL LEWIS C |
10,000 | $1.07 |
PELL LEWIS C |
13,200 | $1.11 |
PELL LEWIS C |
5,600 | $1.10 |
PELL LEWIS C |
1,000,000 | $0.00 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
